

## PREAMBLE

- Cardiovascular Disease: Impact of Biomarkers, Proteomics, and Genomics** F.S. Apple, L. Cullen, G.M. Felker, G. Ginsburg, and D. Morrow **1**

## INTERVIEW

- An Interview with Robert Califf** M. Landau **5**

## REFLECTION

- Apolipoprotein E: Remarkable Protein Sheds Light on Cardiovascular and Neurological Diseases** R.W. Mahley **14**

## EDITORIALS

- One Shot to Rule Out: Does the Limit of Detection of a High-Sensitivity Troponin Assay Hit the Mark?** R. Body and C. Reynard (see articles on pages 369, 394, and 403, letter to the editor page 431) **21**

- Reconciling Systems for Acute Myocardial Infarction Definition and Coding Classification** L.K. Newby (see article on page 415) **24**

- The Role of Emerging Biomarkers in Unraveling the Complex Biology Underlying Associations between HDL Cholesterol and Cardiovascular Diseases** A.M. Small, N.N. Mehta, and D.J. Rader (see article on page 288) **27**

- Troponin Autoantibodies: From Assay Interferent to Mediator of Cardiotoxicity** J.Y. Park and A.S. Jaffe (see article on page 343) **30**

## PERSPECTIVE

- Demystifying HDL Cholesterol—A “Human Knockout” to the Rescue?** A.V. Khera and P.M. Ridker **33**

## Q&A

- Best Practices for Monitoring Cardiac Troponin in Detecting Myocardial Injury** Moderator: F.S. Apple; Experts: A.S. Jaffe, S. Sharkey, P. Kavsak, M.C. Kontos, A.K. Saenger, and S. Smith **37**

## CLINICAL CASE STUDY

- A 61-Year-Old Woman with Muscle Fatigue and Increased Cardiac Troponin** W.A. Parsonage, J.E. Mikli, J.C. Nisbet, C. Hamilton-Craig, and G.A. Marshall **45**

- Commentary** W.W.M. Pim Pijnappel, P.A. van Doorn, and A.T. van der Ploeg **48**

- Commentary** A.S. Jaffe **48**

## MINI-REVIEWS


- Natriuretic Peptides and Analytical Barriers** V.C. Vasile and A.S. Jaffe **50**

- Interpreting Cardiac Biomarkers in the Setting of Chronic Kidney Disease** C.R. deFilippi and C.A. Herzog **59** 

- Evolving Use of Natriuretic Peptides as Part of Strategies for Heart Failure Prevention** K. McDonald and M. Wilkinson **66**

- Cardiac Troponin Assays: Guide to Understanding Analytical Characteristics and Their Impact on Clinical Care** F.S. Apple, Y. Sandoval, A.S. Jaffe, and J. Ordonez-Llanos, for the IFCC Task Force on Clinical Applications of Cardiac Bio-Markers **73**

- Consensus or Controversy?: Evolution of Criteria for Myocardial Infarction After Percutaneous Coronary Intervention** P. Tricoci **82**

- Biomarkers for Clinical Decision-Making in the Management of Pulmonary Embolism** E. Giannitsis and H.A. Katus **91** 

- Myocardial Infarction Type 2 and Myocardial Injury** Y. Sandoval and K. Thygesen **101** 

- Biochemistry, Therapeutics, and Biomarker Implications of Nephrylsin in Cardiorenal Disease** Y. Chen and J.C. Burnett, Jr. **108**

## REVIEWS

- Issues and Challenges in Diagnostic Sequencing for Inherited Cardiac Conditions** R. Walsh and S.A. Cook **116**

*continued*

## REVIEWS, *continued*



**Early Rule-Out and Rule-In Strategies for Myocardial Infarction** L.A. Cullen, N.L. Mills, S. Mahler, and R. Body **129**

**Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease** K.C. Wollert, T. Kempf, and L. Wallentin **140**

**Application of Biomarkers for Risk Stratification in Patients with Atrial Fibrillation** Z. Hijazi, J. Oldgren, A. Siegbahn, and L. Wallentin **152**

**State of the Art: Blood Biomarkers for Risk Stratification in Patients with Stable Ischemic Heart Disease** T. Omland and H.D. White **165**

**Use of Pharmacogenetic Information in the Treatment of Cardiovascular Disease** K. Friede, J. Li, and D. Voora **177**

**Use of Biomarkers in Predicting the Onset, Monitoring the Progression, and Risk Stratification for Patients with Type 2 Diabetes Mellitus** B.M. Scirica **186**

**The Changing Face of HDL and the Best Way to Measure It** S.K. Karathanasis, L.A. Freeman, S.M. Gordon, and A.T. Remaley **196**

**Beyond Natriuretic Peptides for Diagnosis and Management of Heart Failure** N.E. Ibrahim and J.L. Januzzi Jr. **211**

**Application of Cardiac Troponin in Cardiovascular Diseases Other Than Acute Coronary Syndrome** K.M. Eggers and B. Lindahl **223**

**Biomarkers and Genetics in Peripheral Artery Disease** S. Hazarika and B.H. Annex **236**

## OPINIONS

**A Roadmap to Successful Clinical Proteomics** I. Wright and J.E. Van Eyk **245**

**Biomarkers for Cardiovascular Screening: Progress or Passé?** B.M. Everett and P.M. Ridker **248**

**Where Are the Stroke Markers?** W.F. Peacock **252**

**Genomics-Inspired Biomarkers and Diagnostics—Where Are They?** G.S. Ginsburg **255**

**Payer Perspectives on Coverage of Biomarker Testing in Cardiovascular Disease** S.R. Tunis and D.A. Messner **258**

## POINT/COUNTERPOINT

**Point: The Use of Sex-Specific Cutpoints for High-Sensitivity Cardiac Troponin Assays** L.A. Cullen and N.L. Mills **261**

**Counterpoint: Potential Concerns Regarding the Use of Sex-Specific Cutpoints for High-Sensitivity Troponin Assays** E. Giannitsis **264**

## ARTICLES

### LIPIDS, LIPOPROTEINS, AND CARDIOVASCULAR RISK FACTORS

**A Novel Lipid Biomarker Panel for the Detection of Heart Failure with Reduced Ejection Fraction** M. Mueller-Hennessen, H.-D. Düngen, M. Lutz, T.D. Trippel, M. Kreuter, J. Sigl, O.J. Müller, E. Tahirovic, H. Witt, P. Ternes, S. Carvalho, E. Peter, D. Rein, P. Schatz, F. Herth, E. Giannitsis, T. Weis, N. Frey, and H.A. Katus **267**

**Plasma N-terminal Prohomatostatin and Risk of Incident Cardiovascular Disease and All-Cause Mortality in a Prospective Observational Cohort: the PREVEND Study** A. Abbasi, L.M. Kienerker, E. Corpeleijn, R.T. Gansevoort, R.O.B. Gans, J. Struck, R.A. de Boer, H.L. Hillege, R.P. Stolk, G. Navis, and S.J.L. Bakker **278**

**A Novel Protein Glycan-Derived Inflammation Biomarker Independently Predicts Cardiovascular Disease and Modifies the Association of HDL Subclasses with Mortality** R.W. McGarrah, J.P. Kelly, D.M. Craig, C. Haynes, R.C. Jessee, K.M. Huffman, W.E. Kraus, and S.H. Shah (*see editorial on page 27*) **288**

**Increased Trimethylamine N-Oxide Portends High Mortality Risk Independent of Glycemic Control in Patients with Type 2 Diabetes Mellitus** W.H.W. Tang, Z. Wang, X.S. Li, Y. Fan, D.S. Li, Y. Wu, and S.L. Hazen **297**

*continued*

## ARTICLES, *continued*

**High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2<sup>o</sup>P - TIMI 50 Trial** A. Eisen, M.P. Bonaca, P. Jarolim, B.M. Scirica, H.D. White, M. Tendera, M. Dellborg, J.C. Nicolau, J. Morais, K.A.A. Fox, E.A. Bohula, S.A. Murphy, E. Braunwald, and D.A. Morrow **307**

### PROTEOMICS AND PROTEIN MARKERS

**C-Type Natriuretic Peptides in Coronary Disease** T.C.R. Prickett, R.N. Doughty, R.W. Troughton, C.M. Frampton, G.A. Whalley, C.J. Ellis, E.A. Espiner, and A.M. Richards **316**

**Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease** E. Hagström, C. Held, R.A.H. Stewart, P.E. Aylward, A. Budaj, C.P. Cannon, W. Koenig, S. Krug-Gourley, E.R. Mohler III, P.G. Steg, E. Tarka, O. Östlund, H.D. White, A. Siegbahn, and L. Wallentin, on behalf of the STABILITY Investigators **325**

**Association of Repeatedly Measured High-Sensitivity-Assayed Troponin I with Cardiovascular Disease Events in a General Population from the MORGAM/BiomarCaRE Study** M.F. Hughes, F. Ojeda, O. Saarela, T. Jørgensen, T. Zeller, T. Palosaari, M.G. O'Doherty, A. Borglykke, K. Kuulasmaa, S. Blankenberg, and F. Kee **334**

**Anti-Cardiac Troponin Autoantibodies Are Specific to the Conformational Epitopes Formed by Cardiac Troponin I and Troponin T in the Ternary Troponin Complex** A.V. Vylegzhanina, A.E. Kogan, I.A. Katrukha, O.V. Antipova, A.N. Kara, A.V. Bereznikova, E.V. Koshkina, and A.G. Katrukha (see editorial on page 30) **343**

**Specificity of B-Type Natriuretic Peptide Assays: Cross-Reactivity with Different BNP, NT-proBNP, and proBNP Peptides** A.K. Saenger, O. Rodriguez-Fraga, R. Ler, J. Ordonez-Llanos, A.S. Jaffe, J.P. Goetze, and F.S. Apple **351**

**Unraveling the Molecular Complexity of O-Glycosylated Endogenous (N-Terminal) pro-B-Type Natriuretic Peptide Forms in Blood Plasma of Patients with Severe Heart Failure** B. Halfinger, A. Hammerer-Lercher, B. Amplatz, B. Sarg, L. Kremser, and H.H. Lindner **359**

**Rapid Rule-Out of Acute Myocardial Injury Using a Single High-Sensitivity Cardiac Troponin I Measurement** Y. Sandoval, S.W. Smith, A.S.V. Shah, A. Anand, A.R. Chapman, S.A. Love, K. Schulz, J. Cao, N.L. Mills, and F.S. Apple (see editorial on page 21) **369**

**Glial Fibrillary Acidic Protein Serum Levels Distinguish between Intracerebral Hemorrhage and Cerebral Ischemia in the Early Phase of Stroke** S. Luger, J. Witsch, A. Dietz, G.F. Hamann, J. Minnerup, H. Schneider, M. Sitzler, K.E. Wartenberg, M. Niessner, and C. Foerch, for the BE FAST II and the IGNITE Study Groups **377**

**Soluble CD146 Is a Novel Marker of Systemic Congestion in Heart Failure Patients: An Experimental Mechanistic and Transcardiac Clinical Study** M. Arrigo, Q.A. Truong, D. Onat, J. Szymonifka, E. Gayat, H. Tolppanen, M. Sadoune, R.T. Demmer, K.Y. Wong, J.M. Launay, J.-L. Samuel, A. Cohen-Solal, J.L. Januzzi Jr., J.P. Singh, P.C. Colombo, and A. Mebazaa **386**

**Immediate Rule-out of Acute Myocardial Infarction Using Electrocardiogram and Baseline High-Sensitivity Troponin I** J.T. Neumann, N.A. Sörensen, F. Ojeda, T. Schwemer, J. Lehmacher, S. Gönner, N. Jarsetz, T. Keller, S. Schaefer, T. Renné, U. Landmesser, P. Clemmensen, N. Makarova, R.B. Schnabel, T. Zeller, M. Karakas, J.W. Pickering, M. Than, W. Parsonage, J. Greenslade, L. Cullen, D. Westermann, and S. Blankenberg (see editorial on page 21) **394**



### EVIDENCE-BASED MEDICINE AND TEST UTILIZATION


**Rule-In and Rule-Out of Myocardial Infarction Using Cardiac Troponin and Glycemic Biomarkers in Patients with Symptoms Suggestive of Acute Coronary Syndrome** C. Shortt, J. Ma, N. Clayton, J. Sherbino, R. Whitlock, G. Pare, S.A. Hill, M. McQueen, S.R. Mehta, P.J. Devereaux, A. Worster, and P.A. Kavsak (see editorial on page 21) **403**

### OTHER AREAS OF CLINICAL CHEMISTRY

**Discordance between ICD-Coded Myocardial Infarction and Diagnosis according to the Universal Definition of Myocardial Infarction** J. Díaz-Garzón, Y. Sandoval, S.W. Smith, S. Love, K. Schulz, S.E. Thorsden, B.K. Johnson, B. Driver, K. Jacoby, M.D. Carlson, K.W. Dodd, J. Moore, N.L. Scott, C.A. Bruen, R. Hatch, and F.S. Apple (see editorial on page 24) **415**

*continued*

## ARTICLES, *continued*

-  **Trimethylamine N-oxide and Risk Stratification after Acute Myocardial Infarction** T. Suzuki, L.M. Heaney, D.J.L. Jones, and L.L. Ng **420**

## CITATION CLASSIC

- Redefining the Gold Standard of Myocardial Infarction Using Troponin T** E.M. Ohman **429**

## LETTER TO THE EDITOR

- Low Concentrations of High-Sensitivity Troponin T at Presentation to the Emergency Department** E. Carlton, J. Kendall, A. Khattab, and K. Greaves (see editorial on page 21) **431**

## CLINICAL CHEMIST

### GENETIC METABOLIC SERIES

- Dilated Cardiomyopathy in a 2-Year-Old Infant** R.W.A. Peake and K.P. Daly **433**

### WHAT IS YOUR GUESS?

- Increased Cardiac Troponin T and N-Terminal B-Type Natriuretic Peptide in a 78-Year-Old Woman Admitted for Dizziness** J.M. Mair **435**

- The Rise and Fall of Cardiac Troponin T** R. Body and G. McDowell **437**

- Gastroesophageal Reflux?** K.W. Dodd and S.W. Smith **438**

- Does This Patient Have Acute Myocardial Infarction?** G.S. Bodor **439**

### UNVEILING THE RIGHT SIDE

- Winter and Spring in the Myocardium** U. Anand **441**

### SCIENCE IN THE ARTS

- Physical Exercise: the Virtual Movement Culture?** M.H. Dominiczak **443**

## ONLINE CONTENT

### PEARLS OF LABORATORY MEDICINE

*Clinical Chemistry* Trainee Council (CCTC) is a free online program for residents and fellows in laboratory medicine. The program provides a wealth of free educational materials and interactive tools, including Podcasts, Guide to Scientific Writing, Question Bank, Pearls of Laboratory Medicine, and much more. The Pearls are brief presentations on one key topic succinctly presented using slides, audio, and transcript supplements.

Join the CCTC today ([traineecouncil.org](http://traineecouncil.org)) for free access to the following Pearls of Laboratory Medicine. With nearly 100 Pearls now available, 2 are highlighted here.

Erin K. Meyer  
Transfusion Support in Hematopoietic Cell Transplant  
10.15428/CCTC.2016.254359

Anh Dinh  
Hepatitis C Laboratory Testing  
10.15428/CCTC.2016.261750

### ACCENT®—CONTINUING EDUCATION CREDIT FOR READERS OF *CLINICAL CHEMISTRY*

For more information go to <http://www.aacc.org/education-and-career/clinical-chemistry-journal-continuing-education-credits>

*continued*

**ACCENT®—CONTINUING EDUCATION CREDIT FOR READERS OF CLINICAL CHEMISTRY, continued**



**ON THE COVER** *Icarus*, plate VIII of the 1947 illustrated book "Jazz" by Henri Matisse (1869-1954). Each year *Clinical Chemistry* devotes a special issue to a topic of current importance to clinicians and laboratory scientists. This year we revisit the topic of cardiovascular disease, especially the impact of biomarkers, proteomics,

and genomics in cardiovascular disease. In addition to the wide variety of review articles and research reports, be sure to read the interview with current FDA Commissioner Robert Califf, in which he discusses not only the FDA but also his own personal experience with heart disease, his groundbreaking work with tissue plasminogen activator, and the people and places that influenced his career. Also be sure to read the five Opinion pieces by experts in the field, where you will find that, regardless of the area of cardiovascular disease discussed, not everyone agrees. Image credit: Archives H. Matisse. ©2016 Succession H. Matisse/Artists Rights Society (ARS), New York.



Technology Corner, podcasts, color figures for Reviews, and Clinical Chemistry Trainee Council sponsored by Department of Laboratory Medicine, Boston Children's Hospital



Clinical Chemistry podcast coming soon to <http://www.clinchem.org>.



Individual articles may be selected to be a part of the Fast Track Program. Articles receive an expedited review, decision, and, if accepted, rapid online publication.



Video available at <http://www.clinchem.org>.



Follow us on Twitter  
[http://twitter.com/Clin\\_Chem\\_AACC](http://twitter.com/Clin_Chem_AACC)



Like us on Facebook  
<http://www.facebook.com/AACCJournals>



Clinical Chemistry apps available on iPhone, iPad, and Android.